Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

23 Mar 2022

Abstract excerpt

Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug interactions, of which the underlying mechanisms remain poorly understood. We hypothesized that antifungal drugs may increase venetoclax exposure through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Antifungal resistance and susceptibility
Share to Cancer therapeutics and mechanisms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35456528
DOI: 10.3390/pharmaceutics14040694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax EliminationPMID 35456528Read ↗

Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemiaSemantic proximity Read ↗

Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study.Semantic proximity Read ↗

Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective studySemantic proximity Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease PatientsSemantic proximity Read ↗

Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.Semantic proximity Read ↗

Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.Semantic proximity Read ↗

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.Semantic proximity Read ↗

Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis.Semantic proximity Read ↗

Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.